These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26861472)

  • 1. Ziconotide Monotherapy: A Systematic Review of Randomised Controlled Trials.
    Brookes ME; Eldabe S; Batterham A
    Curr Neuropharmacol; 2017; 15(2):217-231. PubMed ID: 26861472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal ziconotide for refractory chronic pain.
    Lynch SS; Cheng CM; Yee JL
    Ann Pharmacother; 2006; 40(7-8):1293-300. PubMed ID: 16849624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal ziconotide for neuropathic pain: a review.
    Rauck RL; Wallace MS; Burton AW; Kapural L; North JM
    Pain Pract; 2009; 9(5):327-37. PubMed ID: 19682321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
    Staats PS; Yearwood T; Charapata SG; Presley RW; Wallace MS; Byas-Smith M; Fisher R; Bryce DA; Mangieri EA; Luther RR; Mayo M; McGuire D; Ellis D
    JAMA; 2004 Jan; 291(1):63-70. PubMed ID: 14709577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPIDOL study protocol for the assessment of intrathecal ziconotide antalgic efficacy for severe refractory neuropathic pain due to spinal cord lesions.
    Brinzeu A; Berthiller J; Perreton N; Subtil F; Gervaise C; Luaute J; Mertens P;
    Trials; 2024 Sep; 25(1):595. PubMed ID: 39244617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis-based medicines for chronic neuropathic pain in adults.
    Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziconotide.
    Strigenz T
    J Pain Palliat Care Pharmacother; 2014 Mar; 28(1):73-4. PubMed ID: 24397285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.
    Atanassoff PG; Hartmannsgruber MW; Thrasher J; Wermeling D; Longton W; Gaeta R; Singh T; Mayo M; McGuire D; Luther RR
    Reg Anesth Pain Med; 2000; 25(3):274-8. PubMed ID: 10834782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
    Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
    Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziconotide: an update and review.
    Williams JA; Day M; Heavner JE
    Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.